ArticleFrontiers in public health2025
Retrospective epidemiological analysis of pulmonary tuberculosis in the older adult and characterization of rifampicin resistance-associated
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the prevalence trend of older adult pulmonary tuberculosis (ETB) and the distribution and outcome of rifampicin-resistant Methods: The pulmonary tuberculosis patients' data in Nantong from 2014 to 2023 were from Tuberculosis Information Management Syste and ETB and rifampicin-resistant Results: From 2014 to 2023, the overall standardized incidence of ETB in Nantong showed a trend of rapid decline and tended to a stable trend stabilized. A total of 140 older adult patients with rifampin resistance, aged 60-69 years, 87 cases (62.1%). single-gene mutation Probe E mutations were the most frequent, observed in 39 cases (60.0%). Specifically, 52 cases (80.00%) were resistant to rifampicin, and Probe E of 31 cases (59.62%) showed the most mutations. The outcome of ETB patients with rifampicin resistance were significantly correlated with treatment classification, rifampicin resistance, Xpert MTB first test, and 0-month sequential sputum positivity. Conclusion: The number of ETB in Nantong from 2014 to 2023 showed a rapid decline and stabilized. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.